Page last updated: 2024-11-03

risperidone and Cardiomyopathy, Hypertrophic

risperidone has been researched along with Cardiomyopathy, Hypertrophic in 1 studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Marti, V1

Other Studies

1 other study available for risperidone and Cardiomyopathy, Hypertrophic

ArticleYear
Sudden cardiac death due to risperidone therapy in a patient with possible hypertrophic cardiomyopathy.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:5

    Topics: Adult; Antipsychotic Agents; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Humans; Male; Ris

2005